

## **DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT**

### **Division of Disease Control and Public Health Response**

#### **EPIDEMIC AND COMMUNICABLE DISEASE CONTROL**

##### **6 CCR 1009-1**

*[Editor's Notes follow the text of the rules at the end of this CCR Document.]*

---

**Adopted By the Board of Health on April 19, 2023**

#### **Regulation 1. Reportable Diseases, Conditions, and Related Events**

For the purpose of these regulations, the diseases, conditions, and related events named in the Reportable Diseases, Condition, and Related Event Table (Appendix A) are declared to be potentially dangerous to public health and shall be reportable in accordance with these regulations. In addition, any language specifying “(the) Department” refers to the Colorado Department of Public Health and Environment.

The Board of Health also requires the reporting of any unusual illness, or outbreak, or epidemic of illnesses, which may be of public concern whether or not known to be, or suspected of being, communicable. Such illnesses, outbreaks, or epidemics include, but are not limited to: 1) those which may be a risk to the public and which may affect large numbers of persons such as illnesses transmitted through food, water, animal to person, or from person to person; 2) cases of a newly recognized entity, including novel influenza; 3) those related to a healthcare setting or contaminated medical devices or products; and 4) those related to environmental contamination by any infectious agent or toxic product of such an agent.

The occurrence of a single case of any unusual disease or manifestation of illness which the healthcare provider determines or suspects may be caused by or related to a bioterrorist agent or incident must be reported immediately by telephone to the Department or county, district, or municipal public health agency by the healthcare provider and the hospital, emergency department, clinic, healthcare center, and laboratory in which the person is examined, tested, and/or treated. The same immediate reporting is required for any unusual cluster of illnesses that may be caused by or related to a bioterrorist agent or incident. Bioterrorist agents include, but are not limited to, anthrax, plague, smallpox, tularemia, botulism, viral hemorrhagic fever and brucellosis.

## **Manner of Reporting**

All cases are to be reported with patient's name, date of birth, sex assigned at birth, race, ethnicity, phone number, physical address (including city and county), email address, preferred language and name and address and phone number of responsible physician or other healthcare provider; and such other information as is needed to locate the patient for follow up. The patient's pregnancy status shall be reported for cases of syphilis and HIV. The patient's relevant treatment shall be reported for sexually transmitted infections. For reports from a publicly funded anonymous testing site, as provided in § 25-4-411, C.R.S., the patient's name and address are not required. When hospitalization is a criteria for reporting (e.g., a hospitalized patient with a positive test result for COVID-19, influenza, or RSV), the report shall provide hospital admission date(s) and the name of the facility where the patient is hospitalized. When requested by the department, the report shall also include discharge date(s), ventilator and intensive care unit (ICU) use, and other fields as needed. In addition, all laboratory information reported shall include specimen accession number. For animal bites by dogs, cats, bats, skunks, foxes, raccoons, coyotes, and other wild carnivores, the name and locating information of the owner of the biting animal shall be reported, if known, by the healthcare provider. Reporting requirements for healthcare-associated infections are provided by §25-3-601 et seq., C.R.S. and are reported to the National Healthcare Safety Network (NHSN). Select healthcare-associated infections not covered by, §25-3-601, C.R.S., are listed below in 6 CCR 1009-1 Appendix A and also reported to NHSN. Facilities reporting outbreaks of healthcare-associated infections and those choosing to voluntarily participate in applied public health projects shall make medical records available for review by the Department upon request within a reasonable time frame. In addition, for sexually transmitted infections, the patient's sex at birth, gender identity and relevant treatment shall be reported.

See Appendix A, Reportable Diseases, Condition, and Related Event Table and Footnotes to determine time frame for reporting (from diagnosis or test result), who shall report, the reporting area, whether laboratory information is required for a report, and whether an isolate or clinical material must be sent to the Department, Laboratory Services Division.

Reports on hospitalized patients may be made part of a report by the hospital as a whole instead of reports from individual providers.

The Department shall develop systems and forms for reporting for physicians, other healthcare providers and hospitals. When hospitals and laboratories transmit disease reports electronically using systems and protocols developed by the Department or Federal agencies that ensure protection of confidentiality, such reporting is acceptable and is considered good faith reporting.

## **Regulation 2. Reporting by Individuals**

Where Reporter = 'P' in the Appendix A, Reportable Diseases Table, cases of diseases shall be reported by the physician or other healthcare provider and by other persons either treating or having knowledge of a reportable disease, including, but not limited to coroners, persons in charge of hospitals or other institutions licensed by the Department (or their designees), persons in charge of schools (including school nursing staff), licensed day care centers, persons in charge of institutions of higher education or their designee, or any other person providing testing and/or counseling to a person with a sexually transmitted infection.

### **Regulation 3. Laboratory Reporting**

Where Reporter = 'L' in the Appendix A, Reportable Diseases, Condition, and Related Event Table, cases of diseases shall be reported with the information required in Regulation 1 by the laboratory, or by an outpatient clinic that performs laboratory testing on site, whether or not associated with a hospital. The following laboratories shall also report: 1) out-of-state laboratories that maintain an office or collection facility in Colorado or arrange for collection of specimens in Colorado; and 2) in-state laboratories that send specimens to out-of-state referral laboratories. The case shall be reported by a laboratory when a result diagnostic of or highly correlated with clinical illness is found. Laboratory assays which demonstrate only immunity should not be reported (for example, a single elevated rubella antibody titer obtained during routine prenatal screening should not be reported).

For organisms so noted in Appendix A, Reportable Diseases, Condition, and Related Event Table, testing laboratories shall routinely submit bacterial culture isolates or patient clinical material that yields positive findings to the Department, Laboratory Services Division. Clinical material is defined as: (i) A culture isolate containing the infectious organism for which submission of material is required, or (ii) If an isolate is not available, material containing the infectious organism for which submission of material is required, in the following order of preference: (A) a patient specimen; (B) nucleic acid; or (C) other laboratory material.

All specimens shall be accompanied by the following information: (a) Patient's name, date of birth, sex assigned at birth, race, ethnicity, phone number, physical address (including city and county), email address, and preferred language; pregnancy status shall be reported for cases of syphilis and HIV (b) Name and address and phone number of responsible physician or other healthcare provider (c) Name of disease or condition (d) Laboratory information - test name, collection date and specimen type. Laboratories should make an effort to report all test results electronically, whenever possible.

### **Regulation 4. Treatment and Control of Tuberculosis**

The emergence of multiple drug-resistant tuberculosis in this country and state dictates a coherent and consistent strategy in order to protect the public health from this grave threat. The underlying principles of disease control expressed in the following rules are as follows: use of the most rapid and modern diagnostic methods by laboratories, rapid reporting, full patient compliance with medical treatment, and prevention of spread of tuberculosis in healthcare settings. The tuberculosis statute (§ 25-4-501, et seq., C.R.S.) covers subject matters not included in these regulations.

- A. All confirmed or suspected cases of active tuberculosis disease, regardless of whether confirmed by laboratory tests, shall be reported to the Department or county, district, or municipal public health agency within 1 working day by physicians, healthcare providers, hospitals, private and public laboratories, other similar private or public institutions, or any other person providing treatment to the confirmed or suspected case. The reports shall include the following information: the patient's name, date of birth, sex assigned at birth, race, ethnicity, phone number, physical address (including city and county), email address, preferred language, name and address and phone number of the reporting physician or other healthcare provider or agency; and such other information as is needed to locate the patient for follow-up. If reported by a physician, the physician shall also give the evidence upon which the diagnosis of tuberculosis was made, the part of the body affected, and the stage of disease.
- B. Physicians, healthcare providers, and healthcare facilities shall report within 4 calendar days the following tuberculin skin test (TST) or Interferon-Gamma Release Assay (IGRA) result if it occurs in a healthcare worker, correctional facility worker, or detention facility worker; a positive TST (defined as = or > 5 mm induration) or positive IGRA test (based on manufacturer's interpretation criteria) if the worker has had prolonged or frequent face-to-face contact with an infectious tuberculosis case.

- C. Laboratories shall report within 1 working day any result diagnostic of or highly correlated with active tuberculosis disease, including culture positive and nucleic acid amplification tests (NAAT) positives for *Mycobacterium Tuberculosis (MTB)* and sputum smears positive for acid fast bacilli, and shall report the results of tests for antimicrobial susceptibility performed on positive cultures for tuberculosis.
- D. Results must be reported by the laboratory which performs the test, but an in-state laboratory which sends specimens to an out-of-state referral laboratory is also responsible for reporting the results.
- E. When a laboratory performs a culture that is positive for *Mycobacterium tuberculosis*, the laboratory shall submit a sample of the isolate to the Department, Laboratory Services Division no later than one working day after the observation of positive findings.
- F. The Department or county, district, or municipal public health agency is authorized to perform evaluations of the timeliness of laboratory diagnostic processes. The data collected in an evaluation may include the mean, median, and range for the following indices: the length of time from specimen collection to isolation; the length of time from isolation of an organism to identification of the organism as *Mycobacterium tuberculosis*; and the length of time from isolation until antimicrobial susceptibility test results are finalized. The Department or county, district, or municipal public health agency shall provide the laboratory and hospital the results of its evaluation, including comparison of the laboratory indices to norms for other similar laboratories.
- G. The Board of Health determines that to prevent the emergence of multi drug-resistant tuberculosis (MDR-TB), it is necessary, appropriate and good medical practice for persons with active tuberculosis disease to receive directly observed therapy (DOT) throughout the treatment for their disease. All healthcare providers and healthcare organizations are required to provide DOT for patients with active tuberculosis disease for the full course of therapy, unless a variance for a particular patient from this requirement is approved by the tuberculosis control program of the Department or tuberculosis clinic at the Public Health Institute at Denver Health. DOT is not required for patients with extrapulmonary tuberculosis disease provided that the presence of pulmonary tuberculosis has been investigated and excluded. In applicable situations, a variance shall be granted in accordance with § 25-4-506(3), C.R.S.

Healthcare providers and healthcare organizations shall report to the Department or county, district, or municipal public health agency within 7 calendar days the name of any patient on DOT who has missed one dose. When requested by healthcare providers and healthcare organizations, the county, district, or municipal public health agency will ensure the provision of DOT to outpatients with active tuberculosis disease and this shall fulfill the requirement for the healthcare providers and healthcare organizations.

- H. All healthcare providers within jails, prisons, and other incarceration facilities and hospitals and healthcare facilities providing inpatient treatment to persons with active tuberculosis disease shall notify the Department or county, district, or municipal public health agency of their intent to discharge a patient and involve the Department or county, district, or municipal public health agency in the discharge planning process prior to discharging the patient from the facility. The intention of the notification and involvement in discharge planning is to discuss the treatment plan for the patient and to assure adequate follow-up and coordination among healthcare providers and public health so that continuity of care and the DOT standard are met.

- I. All licensed hospitals and nursing home facilities shall maintain a registry of the TST and/or IGRA test results of healthcare workers in their facility, including physicians and physician extenders who are not employees of the facility but provide care to or have face-to-face contact with patients in the facility. The facility shall maintain such TST and IGRA test results as confidential medical information. Pursuant to § 25-4-508, C.R.S., authorized personnel of the Department may inspect and have access to such register in the course of an investigation intended to identify sources and contacts of a case of active tuberculosis disease and to control tuberculosis.
- J.
  - (1) With respect to tuberculosis treatment and control, the chief medical officer of a county, district, or municipal public health agency must be a physician licensed to practice medicine in the State of Colorado. The chief medical officer of a county, district, or municipal public health agency may design a program, consistent with good medical practice, of required screening for latent tuberculosis infection. The objective of the program must be to target persons who are at high risk of such infection based on recent local, state, national, or international epidemiologic data concerning the incidence of and risk factors for tuberculosis. The programs shall be limited to screening persons who are at increased risk of tuberculosis (TB) infection or TB disease or who participate in activities or who work in occupations and job categories that have a reasonably large proportion of persons at increased risk of tuberculosis. The programs should be designed so that the initial step in screening is the determination of whether a person has recognized risk factors for tuberculosis and if yes, then said person should undergo a TST or IGRA test and clinical evaluation to rule out TB disease if either test result is positive. If free of signs and symptoms of tuberculosis disease, subsequent testing would be dependent on the results of the TST or IGRA test.
  - (2) If an individual has signs and symptoms consistent with tuberculosis in the infectious stages, the chief medical officer may require examination pursuant to § 25-4-506, C.R.S. The screening may be performed by an institution, organization, or agency acting at the direction of the county, district, or municipal public health agency. The results of the screening shall be given in writing to the person screened. Any person who is found to have latent tuberculosis infection without evidence of active disease shall be counseled and offered appropriate treatment by the agency performing the screening, but the person is not required to take such treatment.
  - (3) Locally required screening programs shall be evaluated and reviewed by the local board of health every three years.
  - (4) Nothing in this rule shall prohibit the Department or county, district, or municipal public health agencies from developing voluntary screening programs, from investigating and screening contacts of suspected or confirmed cases of tuberculosis in a contagious form, or from responding to potential outbreaks of tuberculosis in a community.

**Regulation 5. Investigations to Confirm the Diagnosis, Treatment, and Causes of Epidemic and Communicable Diseases and to Determine Appropriate Methods of Epidemic and Communicable Disease Control**

Investigations may be conducted to confirm the diagnosis, treatment, and causes of identified or potential reportable conditions and shall be considered official duties of the Department or county, district, or municipal public health agencies. Investigations may be conducted to evaluate exposures to known causes of reportable conditions for purposes of case identification and prevention. Such investigations may include, but are not limited to:

- A. Review of pertinent, relevant medical records by authorized personnel, if necessary to confirm the diagnosis; to investigate causes; to identify other cases related to the outbreak or the reported communicable disease in a region, community, or workplace; to determine if a patient with a reportable disease has received adequate treatment to render the person non-infectious or a person exposed to a case has received prophylaxis, if appropriate. Such review of records may occur without patient consent and shall be conducted at reasonable times and with such notice as is reasonable under the circumstances. Such review of records may include negative or inconclusive laboratory results. Where feasible, facilities are encouraged to provide remote electronic access to authorized health department staff for this purpose.
- B. Performing follow-up interview(s) with the case or persons knowledgeable about the case to collect information pertinent and relevant to the cause(s) of or risk factors for the reportable condition.
- C. Medical examination and testing of persons with the explicit consent of such persons.
- D. Obtaining from public or private businesses or institutions the lists of persons with a similar or common potential exposure to a reported case; such exposure may be current or have occurred in the past.
- E. Interviewing or administering questionnaire surveys confidentially to any resident of a community or any agent, owner, operator, employer, employee of a public or private business or institution, that is either epidemiologically associated with a reported case or has had a similar exposure as a reported case.
- F. Collecting and analyzing samples or measurements of items that may be related to the cause of the outbreak or reportable disease.
- G. Taking photographs or videos related to the purpose of the investigation. If the photographs/videos are taken in a business, the employer shall have the opportunity to review the photographs/videos taken or obtained for the purpose of identifying those which contain or might reveal a trade secret.
- H. Entering a public or private entity, such as a business or school, for the purpose of conducting investigations of those processes, conditions, structures, machines, apparatus, devices, equipment, records (including but not limited to current and former employee/student rosters and contact information, schedules, health and medical information, job duties and descriptions, and patron or client contact information), and materials and supplies within the place of employment which are relevant, pertinent, and necessary to the investigation; such investigations shall be conducted during regular working hours or at other reasonable times and with such notice as is reasonable under the circumstances.
- I. Review of workers' compensation claims.
- J. Review of toxic tort or product liability claims filed with state or federal courts within the state.
- K. Review of previously conducted environmental or product sampling data that may be related to the cause of the outbreak or reportable disease.

#### **Regulation 6. Information Sharing**

Whenever a county, district, or municipal public health agency learns of a case of a reportable disease or an epidemic or communicable disease exposure potentially threatening to public health, it shall notify the Department in a timely manner, usually within the timeframe for reporting in Regulation 1.

The Department shall, in turn, notify the appropriate county, district, or municipal public health agency in a timely manner, usually within the timeframe for reporting in Regulation 1, whenever it learns of a case of a reportable disease or it learns of an epidemic or communicable disease exposure potentially threatening to public health.

These requirements shall not apply if the Department and county, district, or municipal public health agencies mutually agree not to share information on reported cases.

Sharing of medical information on persons with reportable diseases between authorized personnel of the Department and county, district, or municipal public health agencies shall be restricted to information necessary for the treatment, control, investigation, and prevention of epidemic and communicable diseases dangerous to public health.

### **Regulation 7. Food Handling and Infected Persons**

No person, while infected with a disease in a communicable form which can be transmitted by foods or who is afflicted by a boil, or an infected wound, shall work in a food processing, milk producing, milk processing or food service setting in any capacity in which there is a likelihood of such person contaminating food or food contact surfaces with pathogenic organisms or transmitting diseases to other persons. The employer is responsible for ensuring the absence from work of an employee with an infectious disease for which there is evidence of transmission to persons in a food service, food processing, milk producing, or milk processing setting, as determined by the Department.

### **Regulation 8. Reporting of Diseases Among Animals and Waiver Process for Rabies Inoculation**

- A. Every veterinarian, livestock owner, veterinary diagnostic laboratory director, or other person having the care of, or knowledge of, the existence of animals having or suspected of having any disease which may endanger public health such as rabies, anthrax, plague, tularemia, encephalitis, bovine spongiform encephalopathy, coronaviruses that cause novel or severe human disease, including SARS-CoV-2, etc., shall promptly report the facts to the Department or county, district, or municipal public health agency.
- B. Pursuant to § 25-4-607 (2), C.R.S., a veterinarian licensed in Colorado may issue a written waiver, as provided in this section, exempting an animal from a rabies vaccination order if the veterinarian, in his or her professional opinion, determines the rabies inoculation is contraindicated due to the animal's medical condition. The terms "waiver" and "exemption" as used in this section are interchangeable. A veterinarian may issue a waiver if:
  - (1) The animal to be exempted has a medical condition defined as "a disease, illness, or other pathological state" for which, in the opinion of the exempting veterinarian, a rabies inoculation is contraindicated;
  - (2) A valid veterinary-client-patient relationship, as defined under § 12-64-103 (15.5), C.R.S., has been established between the veterinarian, owner and animal to be exempted from rabies inoculation;
  - (3) The veterinarian completes and signs the veterinary section of the Exemption from Rabies Vaccination form provided by the Department;
  - (4) The animal owner signs the informed consent section of the Exemption from Rabies Vaccination form;
  - (5) The veterinarian maintains the signed exemption as part of the animal's medical record and provides a copy to the owner;

- (6) The exemption issued is limited to the anticipated duration of the animal's medical condition that precludes inoculation; and
  - (7) The veterinarian provides a copy of the exemption form to the Department or county, district, or municipal public health agency or animal control agency, when requested.
- C. A waiver may not exceed a period of three years from the date of issuance. If the medical condition persists beyond a three year period and, in the professional opinion of a veterinarian licensed in Colorado, the exemption continues to be appropriate, a new waiver may be issued.
- D. Upon receiving a complaint regarding the validity of a rabies inoculation exemption, the executive director or their designee(s) may review Exemption from Rabies Vaccination forms and examine the veterinary records pertaining to the medical condition to determine if the medical condition legitimately contraindicates rabies inoculation. If appropriate, the executive director or their designee(s) may refer the case to the Board of Veterinary Medicine.

### **Regulation 9. Confidentiality**

All personal medical records and reports held or viewed by the Department or county, district, or municipal public health agency in compliance with these regulations shall be confidential information subject to §§ 25-1-122(4) and 25-4-406(1), C.R.S. Reasonable efforts shall be made by the Department to consult with the responsible physician, other healthcare providers, or the medical facility caring for the patient prior to any further follow-up by Department or county, district, or municipal public health agencies. This information is to be used by the public health agencies as source material for necessary disease control efforts and the development of prevention programs.

### **Regulation 10. Use of Sterile Needles, and Cleaning and Disinfection of Other Instruments, Probes, and Devices Used by Practitioners of Acupuncture and Adjunctive Therapies (promulgated by the Executive Director)**

This regulation is promulgated pursuant to § 12-200-1115, C.R.S., which states the Department shall promulgate rules relating to the proper use of sterile needles used in the practice of acupuncture and the sanitation of acupuncture offices.

All parts of the premises of an acupuncture establishment shall be kept in a clean, sanitary, neat, and orderly condition at all times. All surfaces (e.g., tables, counters, chairs, etc.) used in connection with procedures shall be cleaned and disinfected with a disinfectant registered by the U.S. Environmental Protection Agency (EPA) that is approved for use in healthcare settings. Cleaning and disinfection shall occur following each use and according to the disinfectant manufacturer label instructions.

Puncturing devices shall be defined as any needle, instrument, probe, or other devices utilized by practitioners of acupuncture, or adjunctive therapies, that punctures the skin or enters tissue of any patient/client. Needles and other puncturing devices shall be sterile and disposable single-use items that are appropriately discarded immediately after use in an appropriate sharps container, and shall never be used on more than one patient/client. The Food and Drug Administration (FDA) requires that sterile needles be used and always labeled for single patient use.

Equipment shall be defined as any item utilized by practitioners of acupuncture, or adjunctive therapies, that serve as vehicles for needles or other puncturing devices. These items do not puncture the skin or enter the tissue. Equipment shall either be disposable, single-use items (preferred), or thoroughly cleaned and disinfected between each patient/client use according to the manufacturers' instructions. If there are no manufacturers' instructions for how to clean and disinfect the equipment, the equipment shall not be used on more than one patient and disposed of properly.



Acupuncture and adjunctive therapies where sterile needles and puncturing devices are used shall only be performed by licensed practitioners. Prior to and after each treatment of acupuncture, the practitioner shall perform hand hygiene by either washing their hands with soap and water or using an alcohol-based hand sanitizer.

### **Regulation 11. Sexually Transmitted Infections**

The Board of Health recognizes that non-sexual transmission may occur for some infections, and in individual cases, based on clinical and epidemiologic information, the responsible physician or other healthcare provider may conclude the patient's infection was not sexually acquired.

Information concerning testing, treatment, causes, or the prevention of sexually transmitted infections (STIs) shall be shared, to the minimum extent necessary to achieve the public health purpose, between the appropriate county, district, or municipal public health agency, contracted agency, Ryan White Comprehensive Human Immunodeficiency Virus (HIV) Resources Emergency Act-funded agency, other health agency or person providing direct services related to STIs and the Department, as provided by § 25-4-406(1)(b), C.R.S.

With respect to Regulation 5, investigations related to STIs will be limited to the information necessary to confirm the diagnosis, treatment, source of infection, and identification of measures that may be used to prevent additional STIs. The Department shall destroy personal identifying information of all persons with CD4 or viral load results if the investigation subsequent to the report finds no evidence of a STI.

Section 25-4-411 (1)(a), C.R.S., requires the Department to conduct an anonymous counseling and testing program for persons considered to be at high risk for the acquisition of HIV. The provision of confidential counseling and testing for HIV is the preferred screening service for detection of HIV infection. Local boards of health who provide HIV counseling and testing through a contractual agreement with the Department shall consider the need for an anonymous HIV testing option in their jurisdiction, upon petition. The consideration of this option must provide an opportunity for public comment in a public forum, including anonymous testimony presented in writing or through an organization. Local boards of health electing to provide confidential HIV testing with an anonymous option must do so in conjunction with publicly-funded HIV testing and counseling projects.

#### **Operational Standards**

- A. All persons providing HIV testing and counseling at a publicly funded HIV testing and counseling project in a non-health-care setting will have completed an HIV testing and counseling course approved by the Department.
- B. All persons performing partner services will have completed courses concerning introduction to STI interviewing and partner notification, and other related courses as specified by the Department.
- C. Of all HIV tests performed at a publicly funded HIV testing and counseling project, 99% of those persons testing HIV positive will receive test results and appropriate post-test counseling related to those test results. Publicly funded HIV testing sites shall make a good faith effort to inform all persons of their test results and shall provide pertinent HIV prevention counseling and referrals.
- D. All persons newly diagnosed with HIV will be referred for partner services and assessed for linkage to care services. A minimum of 75% of those offered partner services will receive an interview and appropriate referrals. Partner services standards will be determined by the best practices guidance and code of conduct standards for STI prevention providers developed by the Department. These standards shall be made publicly accessible.

- E. Operational and evaluation standards for HIV testing and counseling sites will be determined by the best practices guidance developed by the Department.
- F. In accordance with § 25-4-404(2), C.R.S., the Department shall create and maintain guidelines, subject to approval by the Board of Health, concerning the public health procedures described in §§ 25-4-412 and 25-4-413, C.R.S. These guidelines will include code of conduct standards for the delivery of partner services and clients' rights, responsibilities and protections.

**Appendix A. Reportable Diseases, Condition, and Related Event Table**

Disease/Event	Pathogen/Organism	Time*	Reporter <sup>1</sup>	Specimen Source(s) <sup>2</sup>	Send Clinical Material <sup>3</sup>
<i>Acinetobacter baumannii</i> , carbapenem-resistant (CRAB) <sup>4</sup>	Carbapenem-resistant <i>Acinetobacter baumannii</i> (species in the <i>A.baumannii</i> complex, e.g., <i>A. baumannii</i> , <i>A. calcoaceticus</i> , <i>A. lactucae</i> , <i>A. nosocomialis</i> , <i>A. pittii</i> , <i>A. seifertii</i> , etc.)	4 days	L	All	Required
Acute flaccid myelitis		4 days	P		Upon request
Animal bites by dogs, cats, bats, skunks, foxes, raccoons, coyotes, or other wild carnivores <sup>5,6</sup>		24 hrs	P		Not applicable
Animal bites by mammals not listed above <sup>5</sup>		4 days	P		Not applicable
Anthrax <sup>5</sup>	<i>Bacillus anthracis</i>	Immed	L & P	All	Required
Arboviral Disease	Eastern equine encephalitis, Japanese encephalitis, LaCrosse encephalitis virus, California encephalitis serogroup, Powassan virus, St. Louis encephalitis virus and Western equine encephalitis virus	4 days	L	All	Upon request
Blastomycosis	<i>Blastomyces</i> species	4 days	L & P	All	Upon request
Botulism <sup>5</sup>	<i>Clostridium botulinum</i>	Immed	L & P	All	Upon request
Brucellosis <sup>5</sup>	<i>Brucella</i> species	4 days	L & P	All	Required
Campylobacteriosis	<i>Campylobacter</i> species	4 days	L & P	All	Upon request
<i>Candida auris</i> <sup>7</sup>	<i>Candida auris</i>	Immed	L & P	All	Required
Candidemia <sup>8-Metro</sup>	<i>Candida</i> species	30 days	L	Blood	Upon request
Carbapenemase-producing organisms <sup>9</sup>	Positive phenotypic test for carbapenemase production or detection of a carbapenemase gene	4 days	L	All	Required
Chancroid	<i>Haemophilus ducreyi</i>	4 days	L & P	All	Upon request
Chikungunya	Chikungunya virus	4 days	L	All	Upon request
Chlamydia, any site	<i>Chlamydia trachomatis</i>	4 days	L & P	All	Upon request
Cholera <sup>5</sup>	<i>Vibrio cholerae</i>	Immed	L & P	All	Required
CJD and other transmissible spongiform encephalopathies (TSEs) <sup>5</sup>		4 days	P	All	Upon request
<i>Clostridium difficile</i> infection <sup>8-Metro</sup>	<i>Clostridium difficile</i>	30 days	L	All	Upon request
Coccidioidomycosis	<i>Coccidioides</i> species	4 days	L & P	All	Upon request
Colorado tick fever	Colorado tick fever virus	4 days	L	All	Upon request
COVID-19 <sup>10</sup>	<ul style="list-style-type: none"> <li>SARS-CoV-2 (positive NAAT and rapid antigen tests)</li> <li>COVID-19 lineage or sequencing</li> </ul>	4 days	L & P	All	Upon request
COVID-19 <sup>10</sup>	SARS-CoV-2 (negative or inconclusive result on any NAAT test)	4 days	L & P	All	Upon request
COVID-19-associated hospitalization	SARS-CoV-2	4 days	L & P	All	Upon request
Coronavirus – severe or novel	Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome coronavirus, (MERS-CoV) or other severe or novel coronavirus other than SARS-CoV-2	Immed	L & P	All	Upon request

Cryptosporidiosis	<i>Cryptosporidium</i> species	4 days	L & P	All	Upon request
Cyclosporiasis	<i>Cyclospora</i> species	4 days	L & P	All	Upon request
Dengue	Dengue virus	4 days	L	All	Upon request
Diphtheria <sup>5</sup>	<i>Corynebacterium diphtheriae</i>	Immed	L & P	All	Required
Encephalitis <sup>5</sup>		4 days	P	All	Upon request
Enterobacterales, carbapenem-resistant (CRE) <sup>11</sup>	Carbapenem-resistant Enterobacterales including, but not limited to, <i>Escherichia coli</i> , <i>Klebsiella</i> species, <i>Enterobacter</i> species, <i>Citrobacter</i> species, <i>Serratia</i> species, <i>Raoultella</i> species, <i>Providencia</i> species, <i>Proteus</i> species, <i>Morganella</i> species	4 days	L	All	Required
Enterobacterales, extended-spectrum beta-lactamase (ESBL) <sup>8-Boulder,12</sup>	<i>Escherichia coli</i> and <i>Klebsiella</i> species	30 days	L	All	Upon request
<i>Escherichia coli</i> invasive infections <sup>8-BOULDER</sup>	<i>Escherichia coli</i>	30 days	L	Sterile only	Upon request
<i>Escherichia coli</i> O157:H7 and Shiga toxin-producing <i>Escherichia coli</i>	Shiga toxin-producing <i>Escherichia coli</i> <sup>13</sup>	4 days	L & P	All	Required
Giardiasis	<i>Giardia lamblia</i>	4 days	L & P	All	Upon request
Gonorrhea, any site, including disseminated gonorrhea <sup>3</sup>	<i>Neisseria gonorrhoeae</i>	4 days	L & P	All	Upon request
Group A streptococci <sup>14,8-Metro</sup>	<i>Streptococcus pyogenes</i>	4 days	L	Sterile only	Required
Group B streptococci <sup>8-Metro</sup>	<i>Streptococcus agalactiae</i>	30 days	L	Sterile only	Required
<i>Haemophilus influenzae</i>	<i>Haemophilus influenzae</i>	1 working day	L & P	Sterile only	Required
Hantavirus disease <sup>5</sup>	Hantavirus	4 days	L & P	All	Upon request
Healthcare-associated infections <sup>15</sup>		4 days	P		Not applicable
Hemolytic uremic syndrome if <18 years <sup>5</sup>		4 days	P		Upon request
Hepatitis A <sup>5</sup>	Hepatitis A virus (+IgM anti-HAV, +PCR or +NAAT),	1 working day	L & P	All	Upon request
Hepatitis B	Hepatitis B virus (+HBsAg, +IgM anti- HBc, +HBeAg, or +HBV DNA)	4 days	L & P	All	Upon request
Hepatitis C <sup>16</sup>	Hepatitis C virus (+ serum antibody titer and/or + confirmatory assays)	4 days	L & P	All	Upon request
Hepatitis C <sup>16</sup>	Hepatitis C virus (- confirmatory assays)	4 days	L	All	Upon request
Hepatitis, other viral		4 days	P		Upon request
Histoplasmosis	<i>Histoplasma</i> species	4 days	L & P	All	Upon request
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	<ul style="list-style-type: none"> <li>Human immunodeficiency virus</li> <li>CD4 counts (any value)</li> <li>HIV viral load (any value)</li> <li>HIV genotype</li> </ul>	4 days	<ul style="list-style-type: none"> <li>L &amp; P</li> <li>L &amp; P</li> <li>L &amp; P</li> <li>L</li> </ul>	All	Upon request
Influenza-associated death if <18 years		4 days	P		Upon request
Influenza-associated hospitalization	Influenza Virus	4 days	L & P	All	Upon request
Legionellosis	<i>Legionella</i> species	4 days	L & P	All	Upon request
Leprosy (Hansen's Disease)	<i>Mycobacterium leprae</i>	4 days	P		Upon request
Listeriosis	<i>Listeria monocytogenes</i>	4 days	L & P	All	Required

Lyme disease	<i>Borrelia burgdorferi</i>	4 days	L & P	All	Upon request
Lymphogranuloma venereum (LGV)	<i>Chlamydia trachomatis</i>	4 days	L & P	All	Upon request
Malaria <sup>5</sup>	<i>Plasmodium</i> species	4 days	L & P	All	Upon request
Measles (rubeola) <sup>5</sup>	Measles virus	Immed	L & P	All	Upon request
Meningococcal disease <sup>5</sup>	<i>Neisseria meningitidis</i> or gram-negative diplococci	Immed	L & P	Sterile only	Required
Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia <sup>17</sup>	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)	Per CMS <sup>17</sup>	P	Blood	Not applicable
Mpox (monkeypox)	Mpox virus (orthopox virus)	4 days	L & P	All	Upon request
Multisystem Inflammatory Syndrome in Children (MIS-C) if <21 years		4 days	P		Upon request
Mumps <sup>5</sup>	Mumps virus (acute infection)	4 days	L & P	All	Upon request
<i>Mycobacterium</i> , nontuberculous (NTM) <sup>8- Metro</sup>	<i>Mycobacterium</i> species (except <i>tuberculosis</i> complex, <i>M. leprae</i> , and <i>M. goodii</i> )	30 days	L	All	Upon request
Outbreaks - known or suspected of all types - including those transmitted from food, water, person-to-person, and related to a healthcare setting <sup>5</sup>		Immed	L & P		Upon request
Pertussis (whooping cough) <sup>5</sup>	<i>Bordetella pertussis</i>	1 working day	L & P	All	Upon request
Plague <sup>5</sup>	<i>Yersinia pestis</i>	Immed	L & P	All	Required
Poliomyelitis <sup>5</sup>	Poliovirus	Immed	L & P	All	Upon request
<i>Pseudomonas</i> , carbapenem-resistant <sup>18</sup>	<i>Pseudomonas aeruginosa</i>	4 days	L	All	Upon request
Psittacosis	<i>Chlamydia psittaci</i>	4 days	L & P	All	Upon request
Q fever <sup>5</sup>	<i>Coxiella burnetii</i>	4 days	L & P	All	Upon request
Rabies: human (suspected) <sup>5</sup>	Rabies virus (Lyssavirus)	Immed	L & P	All	Upon request
Respiratory syncytial virus-associated death if <18 years	Respiratory syncytial virus	4 days	P		Upon request
Respiratory Syncytial Virus-associated hospitalizations	Respiratory Syncytial Virus	4 days	L & P	All	Upon request
Rickettsiosis	<i>Rickettsia</i> species, including Rocky Mountain spotted fever and typhus groups	4 days	L & P	All	Upon request
Rubella (acute infection) <sup>5</sup>	Rubella virus	1 working day	L & P	All	Upon request
Rubella (congenital) <sup>5</sup>	Rubella virus	4 days	L & P	All	Upon request
Salmonellosis	<i>Salmonella</i> species	4 days	L & P	All	Required
Shigellosis	<i>Shigella</i> species	4 days	L & P	All	Required
Smallpox <sup>5</sup>	Variola virus (Orthopox virus)	Immed	L & P	All	Upon request
<i>Staphylococcus aureus</i> , Vancomycin-non-susceptible <sup>19</sup>	Vancomycin non-susceptible <i>Staphylococcus aureus</i>	4 days	L	All	Required
<i>Streptococcus pneumoniae</i> <sup>20</sup>	<i>Streptococcus pneumoniae</i>	4 days	L	Sterile only	Required
Syphilis <sup>5, 21</sup>	<i>Treponema pallidum</i>	1 working day	L & P	All	Upon request
Tetanus <sup>5</sup>	<i>Clostridium tetani</i>	4 days	P	All	Upon request
Tick-borne relapsing fever <sup>5</sup>	<i>Borrelia</i> species and spirochetemia except <i>burgdorferi</i> species	4 days	L & P	All	Upon request

Toxic shock syndrome <sup>20</sup> (streptococcal and non-streptococcal)	<i>Streptococcus pyogenes</i> and non-streptococcal bacteria	4 days	P	ALL	Upon request
Trichinosis <sup>5</sup>	<i>Trichinella</i> species	4 days	P	All	Upon request
Tuberculosis disease (active) <sup>5</sup>	<i>Mycobacterium tuberculosis</i> <sup>22</sup>	1 working day	L & P	All	Required
Tuberculosis immune reactivity indicated by a positive interferon gamma release assay test (IGRA)	<i>Mycobacterium tuberculosis</i> <sup>23</sup>	4 days	L	All	Not Required
Tularemia <sup>5</sup>	<i>Francisella tularensis</i>	1 working day	L & P	All	Required
Typhoid fever <sup>5</sup>	<i>Salmonella</i> Typhi	1 working day	L & P	All	Required
Varicella (chicken pox) <sup>5</sup>	Varicella virus	4 days	L & P	All	Upon request
Vibriosis	<i>Vibrio</i> species, non-cholera	4 days	L	All	Required
Viral hemorrhagic fever	Crimean-Congo hemorrhagic virus, Ebola virus, Lassa fever virus, Lujo virus, Marburg virus, Guanarito virus, Junin virus, Machupo virus, Sabia virus	Immed	L & P	All	Required
West Nile virus (acute infection)	West Nile virus	4 days	L	All	Upon request
Yellow fever	Yellow fever virus	4 days	L	All	Upon request
Yersiniosis <sup>8-Seven</sup>	<i>Yersinia non-pestis</i> species	4 days	L	All	Required
Zika virus	Zika virus	4 days	L	All	Upon request

All cases are to be reported with patient's name, date of birth, sex assigned at birth, race, ethnicity, phone number, physical address (including city and county), email address, preferred language and name and address and phone number of responsible physician or other healthcare provider; and such other information as is needed in order to locate the patient for follow up. The patient's pregnancy status shall be reported for cases of syphilis and HIV. In addition, all laboratory information reported shall include specimen accession number.

\*Time: 1) "Immed" = by phone, within 4 hours of suspected diagnosis. 2) Unless the term "working day" is specified, "days" refers to calendar days.

- 1 Reporter: The party responsible for reporting is indicated by one of the following: L = Laboratory (whether or not associated with a hospital; by out-of-state laboratories that maintain an office or collection facility in Colorado or arrange for collection of specimens in Colorado; and by in-state laboratories which send specimens to an out-of- state laboratory referral laboratory), P = healthcare provider or other person knowing of or suspecting a case (including but not limited to coroners, persons in charge of hospitals or other institutions licensed by the Department (or their designees), persons in charge of schools (including nursing staff) and licensed day care centers), L & P = Both.
- 2 Specimen sources: A condition is reportable when the pathogen is isolated or detected from any specimen source unless otherwise indicated. A normally "sterile site" is defined as blood, cerebrospinal fluid (CSF), pleural fluid (includes chest fluid, thoracentesis fluid), peritoneal fluid (includes abdominal fluid, ascites), pericardial fluid, bone (includes bone marrow), joint or synovial fluid, needle aspirate or culture of any specific joint, internal body sites (sterilely obtained from biopsy/tissue/abscess/ aspirate/fluid/swab from lymph node, brain, heart, liver, spleen, vitreous fluid, kidney, pancreas, vascular tissue, or ovary). Skin and skin abscesses are not considered sterile sites.

- 3 Testing laboratories shall routinely submit bacterial culture isolates or patient clinical material that yields positive findings to the Department, Laboratory Services Division. The isolate or clinical material shall be received at the Department, Laboratory Services Division no later than one working day after the observation of positive findings. Clinical material is defined as: (i) A culture isolate containing the infectious organism for which submission of material is required, or (ii) If an isolate is not available, material containing the infectious organism for which submission of material is required, in the following order of preference: (A) a patient specimen; (B) nucleic acid; or (C) other laboratory material. All specimens shall be accompanied by the following information: (a) Patient's name, date of birth, sex assigned at birth, race, ethnicity, phone number, physical address (including city and county), email address, and preferred language; pregnancy status shall be reported for cases of syphilis and HIV (b) Name and address and phone number of responsible physician or other healthcare provider; (c) Name of disease or condition; and (d) Laboratory information - test name, collection date and specimen type.
- 4 *Acinetobacter baumannii* (including species in the *A. baumannii* complex, e.g., *A. baumannii*, *A. calcoaceticus*, *A. lactucae*, *A. nosocomialis*, *A. pittii*, *A. seifertii*, etc.) that are resistant to at least one carbapenem (including imipenem, meropenem, or doripenem).
- 5 Report shall be based on the diagnosis or suspected diagnosis of the attending physician or other healthcare provider, whether or not supporting laboratory data are available.
- 6 For animal bites by dogs, cats, bats, skunks, foxes, raccoons, coyotes, and other wild carnivores, the name and locating information of the owner of the biting animal shall be reported, if known, by the healthcare provider or reporter.
- 7 *Candida auris* identified, or any suspected *Candida auris*. Clinical material may not be available for screening tests.
- 8 Condition reportable only among residents of a specific catchment area.  
  
8-METRO Condition reportable only among residents of Denver Metropolitan Area (Adams, Arapahoe, Denver, Douglas, and Jefferson Counties)  
  
8-SEVEN Condition reportable only among residents of seven-county Denver Metropolitan Area (Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas, and Jefferson counties)  
  
8-BOULDER Condition only reportable among residents of Boulder county
- 9 Clinical or screening test positive for a carbapenemase using a phenotypic, molecular test, or next generation sequencing. Common carbapenemase genes include: blaKPC, blaNDM, blaVIM, blaIMP, blaOXA-48, but other carbapenemase genes include but are not limited to: blaSIM, blaGIM, blaSPM, other OXA genes, etc. Phenotypic testing methods include but are not limited to: metallo- $\beta$ -lactamase test, modified Hodge test, Carba NP, carbapenem inactivation method (CIM), modified carbapenem inactivation method (MCIM), EDTA-modified carbapenem inactivation method (ECIM), or immunochromatography tests (ICT). Molecular tests for carbapenemase genes include but are not limited to: Xpert Carba-R, VERIGENE, Streck ARM-D, Cepheid, validated laboratory-developed NAAT, etc. Clinical material may not be available for screening tests.

- 10 All positive SARS-CoV-2 results for all test types except serology/antibody testing and at-home antigen tests are reportable. Any individual as defined in Regulation 2, entity or facility that collects, performs, or tests for SARS-CoV-2 on specimens in Colorado is responsible for reporting all positive SARS-CoV-2 test results. SARS-CoV-2 sequencing lineage and mutation profile results, when performed, shall also be reported. For any NAAT or molecular SARS-CoV-2 tests conducted by CLIA-certified labs, negative and inconclusive results are also reportable. All entities required to report SARS-CoV-2 test result information shall report through CDPHE's electronic laboratory reporting (ELR) platform. Reporting entities can report directly to CDPHE ELR or through CDC PRIME ReportStream application, or other CDPHE-approved third party.
- 11 Enterobacterales including, but not limited to, *Escherichia coli*, *Klebsiella* species, *Enterobacter* species, *Citrobacter* species, *Serratia* species, and *Raoultella* species that are resistant to at least one carbapenem (including imipenem, meropenem, doripenem, or ertapenem); or *Providencia* species, *Proteus* species, *Morganella* species that are resistant to at least one carbapenem (including meropenem, doripenem, or ertapenem); but not including imipenem); or Enterobacterales of any genus and species that test positive for production of carbapenemase (e.g., KPC, NDM, VIM, IMP, OXA-48, others).
- 12 *Escherichia coli* and *Klebsiella* species resistant to at least one extended-spectrum cephalosporin (ceftazidime, cefotaxime or ceftriaxone) or *Escherichia coli* and *Klebsiella* species that test positive for production of an extended-spectrum beta-lactamase (ESBL) demonstrated by a recognized test (e.g., broth microdilution, disk diffusion).
- 13 This includes any Shiga toxin test or O157 antigen test that is positive, even if no culture is performed. If the laboratory does not have the capacity to perform H (flagellar) antigen tests, then *Escherichia coli* O157 should be reported.
- 14 If group A streptococci is isolated from a wound or surgical tissue/specimen and is accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome, the case shall be reported and the isolate shall be submitted.
- 15 Reportable only by facilities that are voluntarily participating in applied public health projects. Appendix B includes a definition of healthcare-associated infections, a list of included infections, and a list of included health facility types.
- 16 All associated results, including negative (nonreactive) and positive (reactive) HCV confirmatory assays from persons who have been diagnosed with or who have laboratory evidence of HCV infection are reportable (e.g., antigen or nucleic acid amplification for HCV RNA [including qualitative, quantitative or genotype testing]).
- 17 Reporting requirement is fulfilled through the Department's access to the National Healthcare Safety Network (NHSN) for those healthcare facilities that are required to report methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia to the Centers for Medicare & Medicaid services (CMS). In these instances these healthcare facilities shall confer rights to the Department to access the NHSN data for these conditions.
- 18 *Pseudomonas aeruginosa* resistant to at least one of the following carbapenems: imipenem, meropenem, or doripenem; OR *P. aeruginosa* that tests positive for production of a carbapenemase (i.e., KPC, NDM, VIM, IMP, OXA, others).
- 19 *Staphylococcus aureus* that are non-susceptible to vancomycin, which include isolates with minimum inhibitory concentration (MIC) of  $\geq 4$  mcg/ml.



- 20 Clinical material shall be submitted from laboratories when the material is from residents of the 5-county metro area (Adams, Arapahoe, Denver, Douglas and Jefferson counties). For Toxic Shock Syndrome, submission of *Streptococcus pyogenes* isolates from residents of the 5-county metro area is required.
- 21 All associated results for syphilis shall be reported including treponemal tests (Enzyme Immunoassay [EIA], Chemoluminescence Assay [CIA], Fluorescent Treponemal Antibody Absorption [FTA-ABS], Polymerase Chain Reaction [PCR], Multiplex Flow Immunoassay [MFI], *Treponema pallidum* Particle Agglutination [TP-PA], *Treponema pallidum* Antibody [TPA]) and Non-treponemal Tests (Rapid Plasma Reagin [RPR], Venereal Disease Research Laboratory [VDRL], Cerebrospinal Fluid [CSF] Quantitative Titers).
- 22 Including (+) AFB sputum smear, culture (regardless of specimen site) and nucleic acid amplification tests (NAAT). See regulation 4f.
- 23 All positive interferon gamma release assays (IGRAs) will be reported by labs capable of electronic laboratory reporting (ELR), and only reported by ELR.

## **Appendix B. Healthcare-Associated Infections**

Definition of a healthcare-associated infection: a localized or systemic condition that results from an adverse reaction to the presence of an infectious agent or its toxins that was not present or incubating at the time of admission to the health facility.

Examples of healthcare-associated infections include:

Bloodstream infections

Bone and joint infections

Cardiovascular system infections

Central nervous system infections

Eye, ear, nose, throat, or mouth infections

Gastrointestinal system infections

Pneumonia

Reproductive tract infections

Skin and soft tissue infections

Surgical site infections

Systemic infections

Urinary tract infections

Antimicrobial resistant infections

Health facility types include:

Acute care hospitals

Ambulatory surgical centers

Birth centers

Convalescent centers

Dialysis treatment clinics/end-stage renal disease facilities

Hospices

Hospitals

Inpatient rehabilitation facilities

Long-term acute care hospitals

Long-term care facilities

Other hospitals (e.g., Psychiatric, Maternity, Speciality)

Outpatient clinics (community clinics; community clinics with emergency centers; rural health clinics; outpatient rehabilitation facilities; outpatient physical therapy, occupational therapy or speech pathology services; and private physician offices)

---

## **Editor's Notes**

### **History**

Regulations 1, 3 eff. 05/30/2007.

Regulation 3 eff. 03/30/2008.

Regulation 8 eff. 03/02/2010.

Regulations 1, 3, 11 eff. 04/14/2010.

Regulations 1, 3, Appendix A eff. 12/30/2010.

Regulations 1, 3 eff. 11/30/2012.

Regulations 1-3, 5, 9 eff. 10/15/2014.

Regulations 1-4, 8, 10, Appendices A-B eff. 11/14/2015.

Entire rule eff. 05/15/2017.

Entire rule eff. 07/15/2018.

Regulations 1, 4, 8.B, 9, 10 paragraph 1, 11, 11.F, Appendix A eff. 06/14/2019.

Regulations 1, 3, 4, 5, 8, Appendix A eff. 10/15/2021.

Regulation 1, Appendix A emer. rules eff. 02/15/2023.

Regulations 1-5, 8, 10, 11, Appendices A, B eff. 06/14/2023.